<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Mol. Biol</journal-id>
<journal-id journal-id-type="publisher-id">gmb</journal-id>
<journal-title-group>
<journal-title>Genetics and Molecular Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1415-4757</issn>
<issn pub-type="epub">1678-4685</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Genética</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28222202</article-id>
<article-id pub-id-type="pmc">5409767</article-id>
<article-id pub-id-type="publisher-id" specific-use="previous-pid">S1415-47572017005004102</article-id>
<article-id pub-id-type="doi">10.1590/1678-4685-GMB-2015-0321</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Human and Medical Genetics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>TSC1</italic> and <italic>TSC2</italic> gene mutations and their implications
for treatment in Tuberous Sclerosis Complex: a review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rosset</surname>
<given-names>Clévia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Netto</surname>
<given-names>Cristina Brinckmann Oliveira</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ashton-Prolla</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label>Laboratório de Medicina Genômica, Centro de Pesquisa Experimental.
Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil</aff>
<aff id="aff2"><label>2</label>Programa de Pós-Graduação em Genética e Biologia Molecular,
Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil</aff>
<aff id="aff3"><label>3</label>Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre
(HCPA), Porto Alegre, RS, Brazil</aff>
<aff id="aff4"><label>4</label>Departamento de Genética, Universidade Federal do Rio Grande do Sul
(UFRGS), Porto Alegre, RS, Brazil</aff>
</contrib-group>
<author-notes>
<corresp id="c1">Send correspondence to Patricia Ashton Prolla. Serviço de Genética
Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350. 90035-903
Porto Alegre, RS, Brazil. E-mail: <email>pprolla@hcpa.edu.br</email>.</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<season>Jan-Mar</season>
<year>2017</year>
</pub-date>
<volume>40</volume>
<issue>1</issue>
<fpage>69</fpage>
<lpage>79</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>3</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017, Sociedade Brasileira de
Genética.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>License information: This is an open-access article distributed under the
terms of the Creative Commons Attribution License (type CC-BY), which permits
unrestricted use, distribution and reproduction in any medium, provided the
original article is properly cited.</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<p>Tuberous sclerosis complex is an autosomal dominant disorder characterized by skin
manifestations and formation of multiple tumors in different organs, mainly in the
central nervous system. Tuberous sclerosis is caused by the mutation of one of two
tumor suppressor genes, <italic>TSC1</italic> or <italic>TSC2.</italic> Currently,
the development of novel techniques and great advances in high-throughput genetic
analysis made mutation screening of the <italic>TSC1</italic> and
<italic>TSC2</italic> genes more widely available. Extensive studies of the
<italic>TSC1</italic> and <italic>TSC2</italic> genes in patients with TSC
worldwide have revealed a wide spectrum of mutations. Consequently, the discovery of
the underlying genetic defects in <italic>TSC</italic> has furthered our
understanding of this complex genetic disorder, and genotype-phenotype correlations
are becoming possible, although there are still only a few clearly established
correlations. This review focuses on the main symptoms and genetic alterations
described in TSC patients from 13 countries in three continents, as well as on
genotype-phenotype correlations established to date. The determination of
genotype-phenotype correlations may contribute to the establishment of successful
personalized treatment for TSC.</p>
</abstract>
<kwd-group>
<title>Keywords:</title>
<kwd>Tuberous sclerosis complex</kwd>
<kwd><italic>TSC</italic> mutations</kwd>
<kwd>genotype-phenotype correlations</kwd>
<kwd>TSC1</kwd>
<kwd>TSC2</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="59"></ref-count>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Tuberous Sclerosis Complex</title>
<p>Tuberous sclerosis, also known as Tuberous sclerosis complex (TSC) is an autosomal
dominant neurocutaneous and progressive disorder, frequently characterized by the
occurrence of multiple tumors in different organs. Penetrance reaches 95% and is
variable; expressivity also varies greatly even within a given family (<xref ref-type="bibr" rid="B34">Northrup <italic>et al.</italic>, 1993</xref>). The
incidence of TSC is 1/10,000 births, and its prevalence in the general population of
Europe has been estimated to be 8.8/100,000 (Orphanet: Tuberous Sclerosis), affecting
multiple ethnic groups (<xref ref-type="bibr" rid="B21">Joinson <italic>et al.</italic>,
2003</xref>).</p>
<sec>
<title>Diagnosis and symptomatology</title>
<p>Tuberous sclerosis has been initially described by von Recklinghausen in 1862. In
1908, Heinrich Vogt established the diagnostic criteria for TSC as the so-called
triad: epilepsy, mental retardation and adenoma sebaceum. As none of these clinical
signs were pathognomonic for TSC, clinical diagnostic criteria were revised by a
consortium in 1998 (<xref ref-type="bibr" rid="B40">Roach <italic>et al.</italic>,
1998</xref>), which proposed three diagnostic categories (definite, probable or
possible TSC) based on the presence of major and/or minor features of the disease.
<xref ref-type="table" rid="t1">Table 1</xref> shows the revised and updated
diagnostic criteria for TSC, established by the same consortium in 2012 (<xref ref-type="bibr" rid="B35">Northrup <italic>et al.</italic>, 2013</xref>). A
definite clinical diagnosis is made when two major features, or one major feature
plus two minor features are present. Importantly, most major features are localized
to the skin and central nervous system. Also, one must consider that the clinical
manifestations of TSC appear at distinct developmental points, and a person with
suspected TSC may need multiple sequential evaluations before a definite clinical
diagnosis can be made.</p>
<table-wrap id="t1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Revised Diagnostic Criteria for Tuberous Sclerosis Complex<xref ref-type="table-fn" rid="TFN1">*</xref>.</title>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1" width="100%">
<col span="1"/>
</colgroup>
<thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Major Features</th>
</tr>
</thead>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">1. Facial
angiofibromas or forehead plaque</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">2. Non-traumatic
ungual or periungual fibroma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">3. Hypomelanotic
macules (more than three)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">4. Shagreen patch
(connective tissue nevus)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">5. Multiple retinal
nodular hamartomas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">6. Cortical
tuber<xref ref-type="table-fn" rid="TFN2">a</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">7. Subependymal
nodule</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">8. Subependymal
giant cell astrocytoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">9. Cardiac
rhabdomyoma single or multiple</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">10.
Lymphangiomyomatosis<xref ref-type="table-fn" rid="TFN3">b</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">11. Renal
angiomyolipoma<xref ref-type="table-fn" rid="TFN3">b</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-top: thin solid; border-bottom: thin solid; border-color: #000000" valign="middle">Minor Features</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">1. Multiple
randomly distributed pits in dental enamel</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">2. Hamartomatous
rectal polyps<xref ref-type="table-fn" rid="TFN4">c</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">3. Bone cysts<xref ref-type="table-fn" rid="TFN5">d</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">4. Cerebral white
matter migration lines <xref ref-type="table-fn" rid="TFN2">a</xref>
<xref ref-type="table-fn" rid="TFN5">d</xref>
<xref ref-type="table-fn" rid="TFN6">e</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">5. Gingival
fibromas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">6. Non-renal
hamartoma<xref ref-type="table-fn" rid="TFN4">c</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">7. Retinal achromic
patch</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">8. “Confetti” skin
lesions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="middle">9. Multiple renal cysts<xref ref-type="table-fn" rid="TFN4">c</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Definite TSC:
Either 2 major features or 1 major feature with 2 minor features</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Probable TSC: One
major feature and one minor feature</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Possible TSC:
Either 1 major feature or 2 or more minor features</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p>Revised Diagnostic Criteria for Tuberous Sclerosis Complex established by a
consortium in 2012 (Northrup <italic>et al.</italic>, 2012).</p>
</fn>
<fn id="TFN2">
<label>a</label>
<p>When cerebral cortical dysplasia and cerebral white matter migration tracts
occur together, they should be counted as one rather than two features of
TSC.</p>
</fn>
<fn id="TFN3">
<label>b</label>
<p>When both lymphangiomyomatosis and renal angiomyolipomas are present, other
features of TSC should be present before a definitive diagnosis is
assigned.</p>
</fn>
<fn id="TFN4">
<label>c</label>
<p>Histologic confirmation is suggested.</p>
</fn>
<fn id="TFN5">
<label>d</label>
<p>Radiographic confirmation is sufficient.</p>
</fn>
<fn id="TFN6">
<label>e</label>
<p>One panel member recommended three or more radial migration lines constitute
a major feature.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>After skin and CNS findings, renal manifestations are the most common abnormalities
associated with TSC. These include renal cell carcinoma, oncocytomas, angiomyolipomas
(in 80% of patients) and renal cystic disease (in 50% of the patients) (<xref ref-type="bibr" rid="B13">Dixon <italic>et al.</italic>, 2011</xref>). Typically,
renal manifestations in children with TSC are first seen in infancy and increase with
age. Angiomyolipomas, one of the leading causes of death in TSC patients, are
multiple and often bilateral. The associated mortality is due to complications when
these lesions become very large. Another consequence of angiomyolipomas is
destruction of the normal renal parenchyma, resulting in renal failure and end-stage
renal disease (<xref ref-type="bibr" rid="B49">Shepherd <italic>et al.</italic>,
1991</xref>). Patients with clinically detectable renal cystic disease usually
have a severe very early-onset polycystic phenotype (about 2% of TSC patients) (<xref ref-type="bibr" rid="B44">Sampson <italic>et al.</italic>, 1997</xref>).</p>
<p>Pulmonary involvement, specifically lymphangioleiomyomatosis (LAM), is the third most
common cause of TSC-associated morbidity, occurring in approximately 35% of female
TSC patients. LAM is caused by proliferation of atypical smooth muscle cells in the
peribronchial, perivascular, and perilymphatic tissues of the lung (<xref ref-type="bibr" rid="B26">Kumasaka <italic>et al.</italic>, 2004</xref>). LAM
occurs almost exclusively in young women, typically presenting between 30 to 35 years
of age. Symptoms have been reported to begin or worsen during pregnancy, suggesting
that LAM may be hormonally influenced (<xref ref-type="bibr" rid="B8">Castro
<italic>et al.</italic>, 1995</xref>).</p>
<p>Skin lesions are detected in 70% of patients with TSC and include hypomelanotic
macules, shagreen patches, confetti-like lesions, forehead fibrous plaque, facial
angiofibromas, and periungual and ungual fibromas (<xref ref-type="bibr" rid="B47">Schwartz <italic>et al.</italic>, 2007</xref>). Depending on studied population,
even as many as 100% of TSC patients younger than five years may present with
hypopigmented macules. An aggregation of reddish papules, appearing on the nose and
cheeks in a characteristic butterfly distribution, belongs to the Vogt triad of
signs. Although usually symmetrical, occasionally they may be found unilaterally
(<xref ref-type="bibr" rid="B23">Jozwiak <italic>et al.</italic>, 1998</xref>).
Facial angiofibromas (adenoma sebaceum) are formed by hamartomatous growth of dermal
connective tissue with rich vasculature and can result in decreased quality of life
since they affect appearance, may cause disfigurement, and are prone to bleeding,
which increases the possibility of infection (<xref ref-type="bibr" rid="B55">Yates,
2006</xref>). Shagreen Patches are areas of thick, irregularly shaped, and
elevated skin, usually found on the lower back. Mean age of appearance is about 8.1
years (<xref ref-type="bibr" rid="B50">Sun <italic>et al.</italic>, 2005</xref>).
Ungual and subungual fibromas are small tumors that grow around and under toenails or
fingernails. Their mean age of appearance is 14.9 years (<xref ref-type="bibr" rid="B50">Sun <italic>et al.</italic>, 2005</xref>) and their prevalence in older
patients (above 30 years) is close to 90%. Forehead plaques appear under the age of
14 years (<xref ref-type="bibr" rid="B23">Jozwiak <italic>et al.</italic>,
1998</xref>), with mean age of appearance being 2.6 years (<xref ref-type="bibr" rid="B50">Sun <italic>et al.</italic>, 2005</xref>).</p>
<p>TSC is also associated with both retinal and nonretinal ocular findings (<xref ref-type="bibr" rid="B43">Rowley <italic>et al.</italic>, 2001</xref>). Hamartomas
are the most common retinal manifestation of TSC and are identified in approximately
40 to 50% of individuals. Fortunately, they rarely compromise vision, although severe
decreases in visual acuity and blindness has been reported in some cases due to
hamartoma enlargement, macular involvement, retinal detachment, and vitreous
hemorrhage (<xref ref-type="bibr" rid="B41">Robertson, 1999</xref>).</p>
<p>Multiple cardiac rhabdomyomas are cardiac tumors most frequently encountered during
infancy and childhood and they occur in approximately 30% of TSC patients. On the
other side, nearly 100% of fetuses with multiple rhabdomyomas have TSC. Cardiac
rhabdomyomas usually do not cause symptoms or hemodynamic compromise, and the natural
history for these lesions is spontaneous regression in the vast majority of cases.
However, a minority of the cases may become symptomatic shortly after birth or in the
first year of life. Finally, hamartomas may also occur in organs of the endocrine
system and rare case reports exist of angiomyolipomas or fibroadenomas in the
pituitary gland, pancreas, or gonads (<xref ref-type="bibr" rid="B36">O’Callaghan and
Osborne, 2010</xref>).</p>
</sec>
</sec>
<sec>
<title>Neurological involvement</title>
<p>Neurologic complications are the most common and often the most impairing aspect of TSC.
Structural neurological abnormalities include cortical tubers, subependymal nodules
(SENs) and subependymal giant cell tumors (SGCTs). Brain tumors in TSC are rare (2 to
10% of patients with TSC and 1.1-1.4% of all pediatric brain tumors) (<xref ref-type="bibr" rid="B14">Frèrebeau <italic>et al.</italic>, 1985</xref>). Cortical
tubers are developmental abnormalities present in more than 88% of children with TSC
(<xref ref-type="bibr" rid="B11">Cuccia <italic>et al.</italic>, 2003</xref>), and
the average number of tubers per patient ranges from 5 to 50 in different studies.
Tubers lead to loss of the classical six-layered cyto-architecture of the cerebral
cortex and are thought to be responsible for more than 75% of the epileptic disorders in
patients with TSC (Orphanet: Tuberous Sclerosis). The second more frequent structural
neurological lesions in children with TSC are SENs, which are small hamartomas that
occur in the walls of the lateral ventricles. Only SENs located in the region of the
Monro foramina may have the potentiality to grow and to transform into SGCTs (5%-20% of
patients). The last but not least important type of encephalic lesion is SGCT, affecting
an average of 10% of children with TSC. SGCTs are benign, slow-growing tumors of mixed
glioneuronal cells including giant cells. They are typically located near the foramen of
Monro, hence they can cause increased intracranial pressure, obstructive hydrocephalus,
focal neurologic deficits and death (Orphanet: Tuberous Sclerosis, 2015). Approximately
90% of TSC patients experience seizures and about 50% have documented cognitive
impairment, autism, or other behavioral disorders.</p>
<p>Epilepsy is likely the most prevalent and challenging clinical manifestation of TSC, and
virtually all subtypes of seizure have been reported. At least one third of patients
develop refractory epilepsy; attention deficit-hyperactivity disorder and psychiatric
comorbidities, such as mood disorders, anxiety, obsessive compulsive behavior and
alcoholism are also frequently present. Among the different sites of tumor development,
the brain remains undoubtedly the most problematic in terms of therapeutic management
and screening. Brain tumors are the cause of more than 50% of deaths among children with
TSC (<xref ref-type="bibr" rid="B53">Webb <italic>et al.</italic>, 1996</xref>).
Intellectual disability has a prevalence of 40%-50% in TSC; 30% are severely affected
with IQs in the very low range, and 70% have IQs in the normal, yet slightly
left-shifted range (<xref ref-type="bibr" rid="B21">Joinson <italic>et al.</italic>,
2003</xref>).</p>
<sec>
<title>Molecular genetics of TSC: the <italic>TSC1</italic> and <italic>TSC2</italic>
genes</title>
<p>Tuberous sclerosis is caused by mutations in one of two tumor suppressor genes:
<italic>TSC1</italic> (9q34) and <italic>TSC2</italic> (16p13.3). The
<italic>TSC1</italic> gene spans about 53kb of genomic DNA with 23 exons coding
for hamartin, a hydrophilic protein with 1164 amino acids and 130 kDa. Hamartin is
expressed in several adult tissues and plays a key role in the regulation of cell
adhesion. This protein shows no homology with any other vertebrate protein. The
<italic>TSC2</italic> gene comprises approximately 43kb of genomic DNA with 41
exons encoding a 5.5 kb transcript and a 1807 amino acid protein, tuberin, with 198
kDa. This protein contains a hydrophilic N-terminal domain and a conserved 163 amino
acid region encoded by exons 34-38, near the C-terminal portion, which has homology
with the Ras superfamily GTPases proteins rap1GAP and mSpa1 (<xref ref-type="bibr" rid="B30">Maheshwar <italic>et al.</italic>, 1997</xref>). Therefore, tuberin is a
GTPase activating protein that regulates the GTP binding and hydrolysing activity of
the Ras superfamily of proteins and helps to regulate cell growth, proliferation and
differentiation. The other domains of tuberin are less conserved, and additional
homologies between tuberin and other proteins have not been identified. <xref ref-type="bibr" rid="B48">Serfontein <italic>et al.</italic> (2011)</xref> used
bioinformatics tools to examine the presence of conserved elements of
<italic>TSC1</italic> and <italic>TSC2</italic> across different organisms. The
analyzed organisms showed a wide range in the degree to which residues implicated in
signalling are conserved (or present at all) in comparison to the human
<italic>TSC1</italic> and <italic>TSC2</italic> sequences. Not surprisingly, the
mammalian proteins of <italic>Rattus norvegicus</italic> and <italic>Mus
musculus</italic> shared the largest number of residues with the human
proteins.</p>
<p>
<xref ref-type="fig" rid="f1">Figure 1A</xref> schematically shows the structure of
<italic>TSC1</italic> and <italic>TSC2</italic> genes, their coding exons and the
main domains of hamartin and tuberin. These proteins bind each other via their
respective coiled-coil domains to form an intracellular complex that integrates
signals to control cellular homeostasis, oxygen levels, presence of nutrients, energy
pool, and stimulation by growth factors. Such signals regulate Rheb (a Ras homologue
enriched in brain), responsible for the activation of mTOR (mammalian target of
rapamycin) kinase. mTOR, in turn, regulates the translation of a significant
proportion of cellular proteins, including those responsible for the control of cell
growth and proliferation (<xref ref-type="bibr" rid="B28">Kwiatkowski,
2003</xref>).</p>
<fig id="f1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>
<italic>TSC1</italic> and T<italic>SC2</italic> gene structure, domains and
distribution of point mutations. (A) Schematic representation of
<italic>TSC1</italic> and <italic>TSC2</italic> exons and the domains of
hamartin and tuberin, respectively, codified by them. The symbols represent the
number of different mutations described at each exon. (B) The graph shows the
percentage of the total number of described mutations that occur at each
<italic>TSC1</italic> and <italic>TSC2</italic> exon.</title>
</caption>
<graphic xlink:href="1415-4757-gmb-1678-4685-GMB-2015-0321-gf01"></graphic>
</fig>
<p>
<xref ref-type="fig" rid="f2">Figure 2</xref> shows the role of the TSC2:TSC1 complex
in the mTOR pathway. Loss of function mutations in <italic>TSC1</italic> or
<italic>TSC2</italic> lead to deregulated expression patterns in this pathway,
abnormal production of the end products, and ultimately promote tumorigenesis. To
date, specific mechanisms by which these loss of function mutations cause disease are
not established. It is suggested that tumor formation is initiated as a consequence
of at least two hits (<xref ref-type="bibr" rid="B24">Knudson, 1971</xref>): as
<italic>TSC1</italic> and <italic>TSC2</italic> are tumor suppressor genes, the
inactivation of both <italic>TSC1</italic> or both <italic>TSC2</italic> alleles is
necessary for benign or malignant tumor formation. The first hit is an inherited
germline mutation in <italic>TSC1</italic> or <italic>TSC2,</italic> which can be
detected in approximately 85% of patients with the clinical features of TSC, and the
second hit is somatic. There are multiple possible mechanisms for somatic
inactivation of the wild-type alleles of <italic>TSC1</italic> and
<italic>TSC2</italic>, including loss of heterozygosity, mutation and promoter
methylation. It is possible that epigenetic silencing mediated by micro-RNAs also
occurs. Moreover, binding of TSC1 to TSC2 appears to stabilize intracellular TSC2
levels since uncomplexed TSC2 is subject to ubiquitin-mediated degradation (<xref ref-type="bibr" rid="B10">Chong-Kopera <italic>et al.</italic>, 2006</xref>).
Thus, TSC1 has a role in stabilizing the complex, while TSC2 has the GTPase activity.
For this reason, inactivating mutations in either gene give rise to the same clinical
disorder. Clearly, both proteins play pivotal roles in several processes that are
crucial for normal brain development. In addition, because they are widely expressed
throughout the mature brain, these proteins likely have important homeostatic
regulatory functions in neurons during adult life.</p>
<fig id="f2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>The role of the TSC2:TSC1 complex in the mTOR pathway. PI3K is activated by
growth factors through direct interaction with receptors or through interaction
with scaffolding adaptors, such as the IRS proteins. These interactions recruit
PI3K to its substrate PtdIns(4,5)<italic>P</italic>2 (PIP2), allowing
generation of the lipid second messenger PtdIns(3,4,5)<italic>P</italic>3
(PIP3). Akt and PDK1 are recruited to the cell plasma membrane through
association with PIP3. This allows Akt to be activated through phosphorylation
on Thr308 by PDK1 and Ser473 by mTORC2 (not shown). Once active, Akt
phosphorylates many downstream targets, including multiple sites on TSC2.
Phosphorylation of TSC2 impairs the GTPase activity of the TSC2:TSC1 complex,
allowing Rheb-GTP to accumulate. Rheb-GTP in excess activates high levels of
mTORC1, which in turn phosphorylates and inhibits 4E-BP1 and activates S6K1 and
S6K2. By this way, mTORC1 influences on cell growth, translation factors
activation and cell nutrition.</title>
</caption>
<graphic xlink:href="1415-4757-gmb-1678-4685-GMB-2015-0321-gf02"></graphic>
</fig>
<p>Although several TSC families exhibit an autosomal dominant pattern of inheritance,
70% of the cases result from <italic>de novo</italic> germline mutations. Linkage
studies initially suggested that there would be equivalent numbers of families with
mutations in each <italic>TSC</italic> gene (<xref ref-type="bibr" rid="B4">Benvenuto
<italic>et al.</italic>, 2000</xref>). However, the frequency of mutations
reported in <italic>TSC2</italic> is consistently higher than in <italic>TSC1;
TSC1</italic> mutations account for only 10% to 30% of the families identified
with TSC. In sporadic TSC, there is an even greater excess of mutations in
<italic>TSC2.</italic> Nonetheless, identification of <italic>TSC1</italic>
mutations appears to be twice as likely in familial cases as in sporadic cases. The
disparity in mutational frequency may reflect an increased rate of germline and
somatic mutations in <italic>TSC2</italic> as compared with <italic>TSC1,</italic> as
well as an ascertainment bias, since mutations in <italic>TSC2</italic> are
associated with more severe disease (<xref ref-type="bibr" rid="B12">Dabora
<italic>et al.</italic>, 2001</xref>; <xref ref-type="bibr" rid="B20">Jansen
<italic>et al.</italic>, 2008</xref>; <xref ref-type="bibr" rid="B25">Kothare
<italic>et al.</italic>, 2014</xref>). In patients with the TSC phenotype and
no identifiable mutations in either <italic>TSC1</italic> or <italic>TSC2</italic>
(15% to 20%), the disease is usually milder (<xref ref-type="bibr" rid="B12">Dabora
<italic>et al.</italic>, 2001</xref>). A milder phenotype has also been
described in rare individuals with mosaicism for mutations in <italic>TSC1</italic>
or <italic>TSC2</italic>. <xref ref-type="bibr" rid="B7">Caignec <italic>et
al.</italic> (2009)</xref> reported a unique family with three independent
pathogenic mutations in <italic>TSC2</italic> mapping to distinct haplotypes. The
three mutations were most likely <italic>de novo</italic>, as parents of the affected
patients did not present any features of TSC. In addition, findings consistent with
gonadal mosaicism were seen in one branch of the family.</p>
</sec>
<sec>
<title>Molecular diagnosis in TSC</title>
<p>The development of novel techniques and great advances in high-throughput genetic
analysis in the last few years made mutation screening of the <italic>TSC1</italic>
and <italic>TSC2</italic> genes feasible. Recent massively parallel sequencing
technologies (Next-Generation Sequencing, NGS) and copy number variation testing
(Multiplex Ligation-dependent Probe Amplification - MLPA and array-Comparative
Genomic Hybridization - aCGH) have been validated for clinical use in many disorders
including TSC, rendering the analysis much faster and more cost-effective.</p>
<p>Extensive studies of the <italic>TSC1</italic> and <italic>TSC2</italic> genes in
patients with TSC have revealed a wide spectrum of mutations. We searched the PubMed
database to retrieve available published literature in English from 1998 to 2014 that
described mutations at <italic>TSC1</italic> and <italic>TSC2</italic> genes and
established genotype-phenotype correlations for tuberous sclerosis disease. The
following keywords were used: <italic>TSC1</italic> mutations; <italic>TSC2</italic>
mutations; tuberous sclerosis complex; <italic>TSC</italic> mutations;
<italic>TSC</italic> molecular analysis; genotype-phenotype correlation on
tuberous sclerosis. Twenty-seven studies were included in the final analysis. <xref ref-type="table" rid="t2">Table 2</xref> summarizes the results obtained in the
main studies performed with unrelated TSC patients worldwide; many of the changes
listed were found for the first time in the investigated population. The most
frequent mutation type is point mutations. Large gene rearrangements are less
frequently reported, both because of their true prevalence in TSC and also because
several studies did not use methodologies that are directed to the identification of
such mutations. As expected, the observed mutation detection rate is not always
complete. In this group, a mutation could exist in an intronic region distant from
the exon-intron boundaries, which could have an effect on the splicing process or
gene regulation, causing a reduction of normal mRNA transcript. Although a third gene
for TSC may exist and explain this lack of mutation at <italic>TSC1</italic> and
<italic>TSC2</italic> genes in some patients, there is currently no concrete
evidence for this. Also, somatic and germ line mosaicism is a credible explanation
for the failure to detect mutations in some patients, and specialized methods can be
used to enhance detection of these specific situations. Most studies in TSC patients
were conducted in Europe and Asia. The largest cohorts are from the Netherlands and
Poland/USA. As expected through observed mutation frequencies, in all populations
described, the germline mutation rate at the <italic>TSC2</italic> locus was higher
than that at the <italic>TSC1</italic> locus. Also, the frequency of small
rearrangements (small insertions/deletions) is higher than missense, nonsense and
splice site mutations in all populations.</p>
<table-wrap id="t2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Type and frequency of mutations found in <italic>TSC</italic> genes in
patients from different studies in the world and diagnostic strategy
(1998-2014).</title>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1" width="7%">
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
</colgroup>
<thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
<tr>
<th align="left" colspan="1" rowspan="3" valign="top">Population</th>
<th align="center" colspan="1" rowspan="3" valign="top">N</th>
<th align="center" colspan="1" rowspan="3" valign="top">Noncoding/polymorphic alterations</th>
<th align="center" colspan="1" rowspan="3" valign="top">No mutation detected
(%)</th>
<th align="center" colspan="4" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="top">
<italic>TSC1</italic>
</th>
<th align="center" colspan="4" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="top">
<italic>TSC2</italic>
</th>
<th align="center" colspan="1" rowspan="3" valign="top">Mutation detection
methods (Reference of the study)</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="2" valign="top">Point mutations
(missense/nonsense)</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="top">Rearrangements</th>
<th align="center" colspan="1" rowspan="2" valign="top">Splice site
mutations</th>
<th align="center" colspan="1" rowspan="2" valign="top">Point mutations
(missense/nonsense)</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="top">Rearrangements</th>
<th align="center" colspan="1" rowspan="2" valign="top">Splice site
mutations</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Small</th>
<th align="center" colspan="1" rowspan="1" valign="top">Large</th>
<th align="center" colspan="1" rowspan="1" valign="top">Small</th>
<th align="center" colspan="1" rowspan="1" valign="top">Large</th>
</tr>
</thead>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr>
<td align="left" colspan="13" rowspan="1" style="border-bottom: thin solid; border-color: #000000" valign="middle">
<bold>Europe</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Germany</td>
<td align="center" colspan="1" rowspan="1" valign="middle">37</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3 (8 1)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing
(<xref ref-type="bibr" rid="B15">Gumbinger <italic>et al.</italic>
2009</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Turkey</td>
<td align="center" colspan="1" rowspan="1" valign="middle">33</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" valign="middle">27 (81)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing
(<xref ref-type="bibr" rid="B2">Apak <italic>et al</italic>.
2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Poland/USA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">224</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">38 (17)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">15</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">31/37</td>
<td align="center" colspan="1" rowspan="1" valign="middle">43</td>
<td align="center" colspan="1" rowspan="1" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">27</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DHPLC/Sequencing;
long-range PCR/qPCR (<xref ref-type="bibr" rid="B12">Dabora <italic>et
al</italic>. 2001</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Netherlands</td>
<td align="center" colspan="1" rowspan="1" valign="middle">490</td>
<td align="center" colspan="1" rowspan="1" valign="middle">76</td>
<td align="center" colspan="1" rowspan="1" valign="middle">128 (26)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/37</td>
<td align="center" colspan="1" rowspan="1" valign="middle">38</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">56/67</td>
<td align="center" colspan="1" rowspan="1" valign="middle">94</td>
<td align="center" colspan="1" rowspan="1" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">43</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing/
Southern blot/ FISH (<xref ref-type="bibr" rid="B45">Sancak <italic>et
al</italic>. 2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Germany</td>
<td align="center" colspan="1" rowspan="1" valign="middle">68</td>
<td align="center" colspan="1" rowspan="1" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" valign="middle">37 (54)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12/4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing/
Southern blot/ FISH (<xref ref-type="bibr" rid="B29">Langkau <italic>et
al</italic>. 2002</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Denmark</td>
<td align="center" colspan="1" rowspan="1" valign="middle">65</td>
<td align="center" colspan="1" rowspan="1" valign="middle">24</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11 (17)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11/9</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DGGE/ Sequencing;
lomg range PCR/MLPA (<xref ref-type="bibr" rid="B39">Rendtorff <italic>et
al</italic>. 2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">United Kingdom</td>
<td align="center" colspan="1" rowspan="1" valign="middle">150</td>
<td align="center" colspan="1" rowspan="1" valign="middle">30</td>
<td align="center" colspan="1" rowspan="1" valign="middle">30 (20)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NI</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NI</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NI</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NI</td>
<td align="center" colspan="1" rowspan="1" valign="middle">22/20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">26</td>
<td align="center" colspan="1" rowspan="1" valign="middle">22</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/ heteroduplex
analysis/pulse field gel electrophoresis/ Southern blot/ long range PCR
(<xref ref-type="bibr" rid="B22">Jones <italic>et al</italic>.
1999</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<bold>SUBTOTAL</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1067</td>
<td align="center" colspan="1" rowspan="1" valign="middle">162</td>
<td align="center" colspan="1" rowspan="1" valign="middle">274 (26)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/57</td>
<td align="center" colspan="1" rowspan="1" valign="middle">63</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">145/140</td>
<td align="center" colspan="1" rowspan="1" valign="middle">197</td>
<td align="center" colspan="1" rowspan="1" valign="middle">68</td>
<td align="center" colspan="1" rowspan="1" valign="middle">91</td>
<td align="left" colspan="1" rowspan="1" valign="middle">-</td>
</tr>
<tr>
<td align="left" colspan="13" rowspan="1" style="border-top: thin solid; border-bottom: thin solid; border-color: #000000" valign="middle">
<bold>Asia</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">India</td>
<td align="center" colspan="1" rowspan="1" valign="middle">24</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12 (50)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing
(<xref ref-type="bibr" rid="B1">Ali <italic>et al</italic>.
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">China</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sequencing (<xref ref-type="bibr" rid="B31">Mi <italic>et al</italic>. 2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Korea</td>
<td align="center" colspan="1" rowspan="1" valign="middle">44</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">31 (70)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DHPLC/Sequencing
(<xref ref-type="bibr" rid="B9">Choi <italic>et al</italic>.
2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
<td align="center" colspan="1" rowspan="1" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DHPLC/Sequencing
(<xref ref-type="bibr" rid="B46">Sasongko <italic>et al</italic>.
2008</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing
(<xref ref-type="bibr" rid="B54">Yamamotoa <italic>et al.</italic>
2002</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">China</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3 (50)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sequencing (<xref ref-type="bibr" rid="B51">Tian <italic>et al</italic>.
2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Malaysia</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">-</td>
<td align="left" colspan="1" rowspan="1" valign="middle">MLPA (<xref ref-type="bibr" rid="B17">Ismail <italic>et al</italic>.
2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Korea</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2 (18)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sequencing/MLPA
(<xref ref-type="bibr" rid="B18">Jang <italic>et al</italic>.
2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Taiwan</td>
<td align="center" colspan="1" rowspan="1" valign="middle">84</td>
<td align="center" colspan="1" rowspan="1" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">20 (24)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12/15</td>
<td align="center" colspan="1" rowspan="1" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DHPLC/Sequencing
(<xref ref-type="bibr" rid="B16">Hung <italic>et al</italic>.
2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">China</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3 (50)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sequencing (<xref ref-type="bibr" rid="B56">You <italic>et al</italic>.
2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<bold>SUBTOTAL</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">184</td>
<td align="center" colspan="1" rowspan="1" valign="middle">31</td>
<td align="center" colspan="1" rowspan="1" valign="middle">59 (32)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">16</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">22/21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">32</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">17</td>
<td align="left" colspan="1" rowspan="1" valign="middle">-</td>
</tr>
<tr>
<td align="left" colspan="13" rowspan="1" style="border-top: thin solid; border-bottom: thin solid; border-color: #000000" valign="middle">
<bold>America</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Southern blot/
heteroduplex/SSCP (<xref ref-type="bibr" rid="B27">Kwiatkowska <italic>et
al</italic>. 1998</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">126</td>
<td align="center" colspan="1" rowspan="1" valign="middle">47</td>
<td align="center" colspan="1" rowspan="1" valign="middle">52 (41)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13/14</td>
<td align="center" colspan="1" rowspan="1" valign="middle">23</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
<td align="left" colspan="1" rowspan="1" valign="middle">SSCP/Sequencing
(<xref ref-type="bibr" rid="B33">Niida <italic>et al</italic>.
1999</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">36</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7 (19)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4/6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sequencing/MLPA
(<xref ref-type="bibr" rid="B38">Qin <italic>et al</italic>.
2010</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<bold>SUBTOTAL</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">183</td>
<td align="center" colspan="1" rowspan="1" valign="middle">58</td>
<td align="center" colspan="1" rowspan="1" valign="middle">59 (32)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0/13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">17/20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">29</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10</td>
<td align="left" colspan="1" rowspan="1" valign="middle">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">
<bold>TOTAL</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1434</td>
<td align="center" colspan="1" rowspan="1" valign="middle">251</td>
<td align="center" colspan="1" rowspan="1" valign="middle">392 (27)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6/81</td>
<td align="center" colspan="1" rowspan="1" valign="middle">99</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">15</td>
<td align="center" colspan="1" rowspan="1" valign="middle">184/181</td>
<td align="center" colspan="1" rowspan="1" valign="middle">258</td>
<td align="center" colspan="1" rowspan="1" valign="middle">75</td>
<td align="center" colspan="1" rowspan="1" valign="middle">118</td>
<td align="left" colspan="1" rowspan="1" valign="middle">-</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN7">
<p>N= number of patients included in the study; SSCP=Single Strand Conformation
Polymorphism; DHPLC=Denaturing High-Performance Chromatography; FISH=
Fluorescent <italic>In Situ</italic> Hybridization; DGGE=Denaturing Gradient
Gel Electrophoresis; MLPA=Multiplex Ligation-Dependent Probe Amplification;
NA=not analyzed in the study; NI=Not informed.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The exponential discovery rate of novel genomic alterations that cause TSC stimulated
the creation and storage of genetic information in mutation databases. In the Human
Genome Mutation Database (HGMD) for instance, 30 unique missense and 59 nonsense
mutations in <italic>TSC1</italic> had been described by 2014, as well as 91 small
deletions, 41 small insertions, 31 splice site mutations and 21 large rearrangements.
In this database, TSC1 mutations correspond to 93% of the mutations, with the largest
number of these occurring in exon 15, which is the largest in basepairs (559).
Proportionally, it corresponds to a mutation frequency of 9.5% (determined as the
percentage of mutations per base pairs, considering the size of each exon) and the
highest mutation frequency is in exon 13 (14.3%). Considering all exons, the average
frequency of observed mutations is 5.9%. Seven of the 23 exons have higher values
(above 9%). Small deletions are responsible for 41% of the disease and small
insertions, for 18.5%. Large rearrangements are responsible for 7% of mutations in
TSC1 at this database. The predicted coiled-coil domain of hamartin corresponds to
exons 17-23, where 21.9% of the mutations are localized. Exons 17-18 are responsible
for interaction with tuberin, and they account for 15.9% of the point mutations
described. Another database, the Leiden Open Variation Database (LOVD), reports 690
unique DNA variants for the <italic>TSC1</italic> gene.</p>
<p>Considering the <italic>TSC2</italic> gene, 183 unique missense and 125 nonsense
mutations gene are described in the HGMD database, as well as 189 small deletions, 99
small insertions, 120 splice site mutations and 148 large rearrangements. Point
mutations correspond to 82.6% of the mutations, with the largest number of these
occurring in exon 33, which is the largest in basepairs (488). Proportionally, this
exon corresponds to a mutation frequency of 15.45%, and the highest mutation
frequency is in exon 37 (22.9%) and exon 38 (22.8%). Considering all exons, average
frequency of observed mutations is 11.0%, a higher number than mutation frequency at
the <italic>TSC1</italic> gene. Twenty-seven of the 41 exons have mutation frequency
values above 9% and an overall mutation number and mutation frequency higher than
that at the <italic>TSC1</italic> gene. Small deletions are responsible for 32% of
the disease versus 41% in the <italic>TSC1</italic> gene, and small insertions for
17% versus 18.5% in the <italic>TSC1</italic> gene. Large rearrangements are not
shown in the table, and are responsible for 17.4% of mutations in
<italic>TSC2</italic>, a higher number than the frequency of large rearrangements
in the <italic>TSC1</italic> gene.</p>
<p>The predicted coiled-coil domain of tuberin corresponds to exon 10 of the
<italic>TSC2</italic> gene, where only 1.8% of small mutations are localized.
Exons 34-38 encode the GAP-domain, responsible for the essential GTPase activaty, and
they account for 18.1% of the point mutations described at this gene, with a high
mutation frequency (95.1%). Exons 37 and 38 have shown the highest mutation frequency
in the <italic>TSC2</italic> gene, and these mutations can have a damage effect on
the protein since the GAP domain can be disrupted. In the Leiden Open Variation
Database, 1925 unique DNA variants on <italic>TSC2</italic> gene have been
reported.</p>
<p>
<xref ref-type="fig" rid="f1">Figure 1A</xref> illustrates the distribution of point
mutations among all exons and domains of the <italic>TSC1</italic> and
<italic>TSC2</italic> genes described in these different studies, and <xref ref-type="fig" rid="f1">Figure 1B</xref> graphically represents the occurrence of
point mutations in each of the <italic>TSC1</italic> and <italic>TSC2</italic> exons
(percentage of the total number of described mutations in the HGMD database that
occurs in each exon). This percentage is not related to exon size, but larger exons
contain more mutations than smaller exons.</p>
<p>Because TSC can be a devastating disease, family members of affected individuals are
often eager to know whether they are carriers of <italic>TSC</italic> mutations.
Currently, with the adventure of next generation sequencing platforms, it became
possible to analyze point mutations in both <italic>TSC1</italic> and
<italic>TSC2</italic> genes at the same time for a lower cost; if no mutations are
detected, the search for large deletions and duplications should proceed. Prenatal
and preimplantation genetic tests are also becoming more widely available. The
mutation status of family members has great implications on genetic counseling.
Furthermore, for all clinical diagnostic criteria, patients with subclinical TSC may
not be correctly diagnosed, and genetic testing is also very important for these
cases.</p>
<p>The second International Tuberous Sclerosis Complex Consensus Conference brought
together 79 experts from 14 countries to finalize diagnostic, surveillance, and
management recommendations for patients with TSC (<xref ref-type="bibr" rid="B35">Northrup <italic>et al.</italic>, 2013</xref>). At this meeting, the most
significant change recommended was the incorporation of genetic testing in the
diagnostic criteria. Molecular testing of the <italic>TSC1</italic> and
<italic>TSC2</italic> genes yields a positive mutation result for 75-90% of
TSC-affected individuals categorized as having definite Clinical Diagnostic Criteria.
The recommendation of the Genetics Panel was to make the identification of a
pathogenic mutation in <italic>TSC1</italic> or <italic>TSC2</italic> an independent
diagnostic criterion, regardless of the clinical findings. This will facilitate the
diagnosis of TSC in some, particularly young individuals, allowing earlier
implementation of surveillance and treatment with a potential for better clinical
outcomes. <italic>TSC1</italic> and <italic>TSC2</italic> genetic variants whose
functional effect is not definitely pathogenic would not be considered a major
diagnostic criterion. Finally, a normal result from <italic>TSC1</italic> and
<italic>TSC2</italic> testing does not exclude TSC, since a fraction of TSC
patients has no mutation identified by conventional genetic testing. Nonetheless, if
the mutation in an affected relative is known, testing for that mutation has very
high predictive value for family members.</p>
</sec>
<sec>
<title>Genotype-phenotype correlations in TSC</title>
<p>The discovery of the underlying genetic defects in <italic>TSC</italic> has furthered
our understanding of this complex genetic disorder and genotype-phenotype
correlations are becoming possible. In a retrospective study, <xref ref-type="bibr" rid="B25">Kothare <italic>et al.</italic> (2014)</xref> analysed a series of 919
TSC patients and found that carriage of a germline <italic>TSC2</italic> mutation was
associated with SENs and SGCTs. Occurrence of tubers, however, did not differ between
carriers of <italic>TSC1</italic> or <italic>TSC2</italic> mutations. In general,
patients with <italic>TSC2</italic> mutation presented with symptoms at a younger
age. <xref ref-type="bibr" rid="B12">Dabora <italic>et al.</italic> (2001)</xref>
analyzed 224 TSC patients and found that seizures, average cortical tuber number and
SEN are more frequent or severe in patients with <italic>de novo TSC2</italic>
mutations than those with <italic>TSC1</italic> mutations. <xref ref-type="bibr" rid="B20">Jansen <italic>et al.</italic> (2008)</xref> also reported a more severe
neurologic phenotype, including an earlier age of seizure onset, lower cognition
index and more tubers in patients with a <italic>TSC2</italic> mutation as compared
to those with a <italic>TSC1</italic> mutation. Another important correlation
involves a subgroup of large genomic deletions at <italic>TSC2</italic> that also
affect the adjacent <italic>PKD1</italic> gene, causing early-onset polycystic kidney
disease (<xref ref-type="bibr" rid="B37">Osborne <italic>et al.</italic>,
1991</xref>).</p>
<p>
<xref ref-type="table" rid="t3">Table 3</xref> shows a compilation of the main
genotype-phenotype correlations described to date. As expected, most
<italic>TSC2</italic> mutations are generally associated with a more severe
phenotype. Only one <italic>TSC2</italic> mutation, R905Q, was associated with milder
disease. This mutation was found in 25 individuals from the same family, with a
phenotype characterized by the complete absence of disfiguring skin lesions,
intractable epilepsy, mental retardation, and severe organ involvement. So, the type
and location of mutations in both <italic>TSC1</italic> and <italic>TSC2</italic>
genes also have an influence in the phenotype. Hamartin and tuberin are known to bind
to at least 40 additional proteins, and thus there are numerous potential and yet
undefined effects of <italic>TSC</italic> gene mutations. Futhermore, it is likely
that other events such as mosaicism, the nature and frequency of the second event of
inactivation of the second allele and the modifying genes, as well as environmental
effects may interfere with the phenotype, which makes it more difficult to establish
clear genotype-phenotype correlations. Moreover, polymorphic and non-pathogenic
variants in the <italic>TSC1</italic> and <italic>TSC2</italic> genes can act as
phenotype modifiers in tuberous sclerosis, and they need to be further explored. To
date, little is known about non-pathogenic variants in these genes, and phenotype
modifiers in tuberous sclerosis have not been identified so far.</p>
<table-wrap id="t3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<title>Genotype-phenotype correlations established for TSC patients.</title>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1" width="14%">
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
</colgroup>
<thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Population</th>
<th align="center" colspan="1" rowspan="1" valign="top">N</th>
<th align="center" colspan="1" rowspan="1" valign="top">Locus of DNA
alteration</th>
<th align="center" colspan="1" rowspan="1" valign="top">Amino acid
change</th>
<th align="center" colspan="1" rowspan="1" valign="top">Type of
alteration</th>
<th align="center" colspan="1" rowspan="1" valign="top">Main associated
symptoms</th>
<th align="center" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">EUA</td>
<td align="center" colspan="1" rowspan="1" valign="top">1039</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mutations in the
<italic>TSC2</italic> gene were more frequent than
<italic>TSC1</italic> gene in patients with retinal findings</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B3">Aronow <italic>et al</italic>.,
2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Poland</td>
<td align="center" colspan="1" rowspan="1" valign="top">170</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic> c.5238-5255del 18pb</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Frameshift</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B42">Rok <italic>et al</italic>.,
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">USA</td>
<td align="center" colspan="1" rowspan="1" valign="top">220</td>
<td align="center" colspan="1" rowspan="1" valign="top">Contiguous deletion
<italic>TSC2-PKD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Large
rearrangement</td>
<td align="left" colspan="1" rowspan="1" valign="top">Arachnoid cysts and
polycystic kidney disease</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B6">Boronat <italic>et al</italic>.,
2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Poland/USA</td>
<td align="center" colspan="1" rowspan="1" valign="top">224</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Seizures, mental
retardation, average tuber count, subependymal nodules, renal
angiomyolipomas, angiofibromas and fibrous forehead plaques were more
common and severe in <italic>TSC2</italic> patients</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B12">Dabora <italic>et al</italic>.,
2001</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Netherlands</td>
<td align="center" colspan="1" rowspan="1" valign="top">490</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Shagreen patches are
more frequent in patients with <italic>TSC1</italic> mutation</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B45">Sancak <italic>et al</italic>.,
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Netherlands</td>
<td align="center" colspan="1" rowspan="1" valign="top">490</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mental retardation is
more frequent in patients with <italic>TSC2</italic> mutation</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B45">Sancak <italic>et al</italic>.,
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Netherlands</td>
<td align="center" colspan="1" rowspan="1" valign="top">490</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Nonsense and
frameshift</td>
<td align="left" colspan="1" rowspan="1" valign="top">Shagreen patches,
forehead plaques, facial angiofibromas, ungual fibromas, renal
angiomyolipomas and renal cysts</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B45">Sancak <italic>et al</italic>.,
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Netherlands</td>
<td align="center" colspan="1" rowspan="1" valign="top">490</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mutations in the GAP
domain</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mental retardation,
seizures and subependymal nodules</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B45">Sancak <italic>et al</italic>.,
2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Korea</td>
<td align="center" colspan="1" rowspan="1" valign="top">11</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mutations in exons
33-41</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cardiac
rhabdomyomas</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B18">Jang <italic>et al</italic>.,
2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">USA</td>
<td align="center" colspan="1" rowspan="1" valign="top">65</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Higher number of cysts
than <italic>TSC1</italic> woman with pulmonary
lymphangioleiomyomatosis</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B32">Muzykewicz <italic>et al.</italic>,
2009</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Canada</td>
<td align="center" colspan="1" rowspan="1" valign="top">19 families</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">R905Q</td>
<td align="center" colspan="1" rowspan="1" valign="top">Missense</td>
<td align="left" colspan="1" rowspan="1" valign="top">Milder disease
severity</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B19">Jansen <italic>et al.</italic>,
2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">USA</td>
<td align="center" colspan="1" rowspan="1" valign="top">478</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic> proximal region (exons 1-22) and distal region
(exons 34-41)</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Missense mutations
and small in-frame deletions or insertions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proximal and distal
<italic>TSC2</italic> mutations showed a significantly higher risk of
infantile spasms compared with mutations in the central region of the
gene</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B52">van Eeghena <italic>et al.</italic>,
2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">USA and Belgium</td>
<td align="center" colspan="1" rowspan="1" valign="top">919</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Any type on
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">More frequent
occurrence of several kinds of seizures/epilepsy subtypes: partial
epilepsy, complex partial seizures, infantile spasms, SENs, SGCTs and
cognitive impairment.</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B25">Kothare <italic>et al</italic>.,
2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">United Kingdom</td>
<td align="center" colspan="1" rowspan="1" valign="top">One case report</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<italic>TSC1</italic> intron 10 (c.1030-3 C &gt; G)</td>
<td align="center" colspan="1" rowspan="1" valign="top">-</td>
<td align="center" colspan="1" rowspan="1" valign="top">Splice site
mutation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild phenotype
(seizures and small number of hypomelanotic macules)</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B5">Blyth <italic>et al</italic>.,
2010</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN8">
<p>N= number of patients included in the study.</p>
</fn>
<fn id="TFN9">
<p>NI=Not informed.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In light of emerging human genetic and molecular knowledge, molecular diagnosis of
TSC and determination of genotyope-phenotype correlations might help in the
establishment of personalized treatment for TSC patients and improve quality of life
among these patients. Continuous studies in this area can guide future directions in
this line.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1">
<p>
<italic>Associate Editor: Carlos F. M. Menck</italic>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Girimaji</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Markandaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sacchidanand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian
patients with tuberous sclerosis complex</article-title>
<source/>Acta Neurol Scand
          <volume>111</volume>
<fpage>54</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">15595939</pub-id>
</element-citation>
</ref>
<ref id="B2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haliloolu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kose</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Anlar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Aysun</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Mutation analysis of TSC2 gene in 33 Turkish familial cases with
tuberous sclerosis</article-title>
<source/>Turk J Pediatr
          <volume>45</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">12718362</pub-id>
</element-citation>
</ref>
<ref id="B3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aronow</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traboulsi</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>AD</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Tuberous sclerosis complex: Genotype/phenotype correlation of retinal
findings</article-title>
<source/>Ophthalmology
          <volume>119</volume>
<fpage>1917</fpage>
<lpage>1923</lpage>
<pub-id pub-id-type="pmid">22608477</pub-id>
</element-citation>
</ref>
<ref id="B4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benvenuto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Braverman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vass</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Cheadle</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wienecke</surname>
<given-names>R</given-names>
</name>
<name>
<surname>DeClue</surname>
<given-names>JE</given-names>
</name>
</person-group>
<year>2000</year>
<article-title>The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell
growth and augments the expression of the TSC2 product tuberin by inhibiting its
ubiquitination</article-title>
<source/>Oncogene
          <volume>19</volume>
<fpage>6306</fpage>
<lpage>6316</lpage>
<pub-id pub-id-type="pmid">11175345</pub-id>
</element-citation>
</ref>
<ref id="B5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blyth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raponi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Treacy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Baralle</surname>
<given-names>D</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Expanding the tuberous sclerosis phenotype: Mild disease caused by a
TSC1 splicing mutation</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <volume>81</volume>
<fpage>350</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="pmid">20185476</pub-id>
</element-citation>
</ref>
<ref id="B6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boronat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Auladell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Eeghen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Arachnoid cysts in tuberous sclerosis complex</article-title>
<source/>Brain Dev
          <volume>36</volume>
<fpage>801</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="pmid">24325802</pub-id>
</element-citation>
</ref>
<ref id="B7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caignec</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kury</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hardouin</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Melki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>David</surname>
<given-names>A</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Three independent mutations in the TSC2 gene in a family with tuberous
sclerosis</article-title>
<source/>Eur J Hum Genet
          <volume>17</volume>
<fpage>1165</fpage>
<lpage>1170</lpage>
<pub-id pub-id-type="pmid">19259131</pub-id>
</element-citation>
</ref>
<ref id="B8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sheperd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lie</surname>
<given-names>JT</given-names>
</name>
</person-group>
<year>1995</year>
<article-title>Pulmonary tuberous sclerosis</article-title>
<source/>Chest
          <volume>107</volume>
<fpage>189</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="pmid">7813275</pub-id>
</element-citation>
</ref>
<ref id="B9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Chae</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Mutational analysis of <italic>TSC1</italic> and <italic>TSC2</italic>
in Korean patients with tuberous sclerosis complex</article-title>
<source/>Brain Dev
          <volume>28</volume>
<fpage>440</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="pmid">16554133</pub-id>
</element-citation>
</ref>
<ref id="B10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong-Kopera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inoki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Garcia-Gonzalo</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>KL</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and
the HERC1 ubiquitin ligase</article-title>
<source/>J Biol Chem
          <volume>281</volume>
<fpage>8313</fpage>
<lpage>8316</lpage>
<pub-id pub-id-type="pmid">16464865</pub-id>
</element-citation>
</ref>
<ref id="B11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuccia</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zuccaro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sosa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Monges</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lubienieky</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Taratuto</surname>
<given-names>AL</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Subependymal giant cell tumor in children with tuberous
sclerosis</article-title>
<source/>Childs Nerv Syst
          <volume>19</volume>
<fpage>232</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="pmid">12715190</pub-id>
</element-citation>
</ref>
<ref id="B12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabora</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Nieto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choy</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Egelhoff</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<year>2001</year>
<article-title>Mutational analysis in a cohort of 224 tuberous sclerosis patients
indicates increased severity of <italic>TSC2</italic>, compared with
<italic>TSC1</italic> disease in multiple organs</article-title>
<source/>Am J Hum Genet
          <volume>68</volume>
<fpage>64</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">11112665</pub-id>
</element-citation>
</ref>
<ref id="B13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Hulbert</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bissler</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Tuberous sclerosis complex renal disease</article-title>
<source/>Nephron Exp Nephrol
          <volume>118</volume>
<fpage>15</fpage>
<lpage>20</lpage>
</element-citation>
</ref>
<ref id="B14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frèrebeau</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Benezech</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Segnarbieux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Harbi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Desy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marty-Double</surname>
<given-names>CH</given-names>
</name>
</person-group>
<year>1985</year>
<article-title>Intraventricular tumors in tuberous sclerosis</article-title>
<source/>Childs Nerv Syst
          <volume>1</volume>
<fpage>45</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">3986841</pub-id>
</element-citation>
</ref>
<ref id="B15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gumbinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rohsbach</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Schulze-Bonhage</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Korinthenberg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zentner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Häffner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fauser</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Focal cortical dysplasia: A genotype-phenotype analysis of
polymorphisms and mutations in the TSC genes</article-title>
<source/>Epilepsia
          <volume>50</volume>
<fpage>1396</fpage>
<lpage>1408</lpage>
<pub-id pub-id-type="pmid">19175396</pub-id>
</element-citation>
</ref>
<ref id="B16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>WL</given-names>
</name>
<etal></etal>
</person-group>
<year>2006</year>
<article-title>Molecular and clinical analyses of 84 patients with tuberous sclerosis
complex</article-title>
<source/>BMC Med Genet
          <volume>7</volume>
<elocation-id>e72</elocation-id>
</element-citation>
</ref>
<ref id="B17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ismail</surname>
<given-names>NFD</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>NMANA</given-names>
</name>
<name>
<surname>Mohseni</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rani</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Hayati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salmi</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Narazah</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Zabidi-Hussin</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Silawati</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Keng</surname>
<given-names>WT</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>Two novel gross deletions of <italic>TSC2</italic> in Malaysian
patients with Tuberous Sclerosis Complex and TSC2/PKD1 Contiguous Deletion
Syndrome</article-title>
<source/>Jpn J Clin Oncol
          <volume>44</volume>
<fpage>506</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="pmid">24683199</pub-id>
</element-citation>
</ref>
<ref id="B18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ki</surname>
<given-names>CS</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Identification of <italic>TSC1</italic> and TSC2 mutations in Korean
patients with Tuberous Sclerosis Complex</article-title>
<source/>Pediatr Neurol
          <volume>46</volume>
<fpage>222</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">22490766</pub-id>
</element-citation>
</ref>
<ref id="B19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sancak</surname>
<given-names>O</given-names>
</name>
<name>
<surname>D'Agostino</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Badhwar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Melanson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tampieri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Koenekoop</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Unusually mild tuberous sclerosis phenotype is associated with
<italic>TSC2</italic> R905Q mutation</article-title>
<source/>Ann Neurol
          <volume>60</volume>
<fpage>528</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="pmid">17120248</pub-id>
</element-citation>
</ref>
<ref id="B20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Braams</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Vincken</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Algra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anbeek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jennekens-Schinkel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>van den Ouweland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Huffelen</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<year>2008</year>
<article-title>Overlapping neurologic and cognitive phenotypes in patients with
<italic>TSC1</italic> or <italic>TSC2</italic> mutations</article-title>
<source/>Neurology
          <volume>70</volume>
<fpage>908</fpage>
<lpage>915</lpage>
<pub-id pub-id-type="pmid">18032745</pub-id>
</element-citation>
</ref>
<ref id="B21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O’Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Learning disability and epilepsy in an epidemiological sample of
individuals with tuberous sclerosis complex</article-title>
<source/>Psychol Med
          <volume>33</volume>
<fpage>335</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">12622312</pub-id>
</element-citation>
</ref>
<ref id="B22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Shyamsundar</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Maynard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Idziaszczyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tomkins</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cheadle</surname>
<given-names>JP</given-names>
</name>
</person-group>
<year>1999</year>
<article-title>Comprehensive mutation analysis of TSC1 and TSC2 - and phenotypic
correlations in 150 families with tuberous sclerosis</article-title>
<source/>Am J Hum Genet
          <volume>64</volume>
<fpage>1305</fpage>
<lpage>1315</lpage>
<pub-id pub-id-type="pmid">10205261</pub-id>
</element-citation>
</ref>
<ref id="B23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Janniger</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Michalowicz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chmielik</surname>
<given-names>J</given-names>
</name>
</person-group>
<year>1998</year>
<article-title>Skin lesions in children with tuberous sclerosis complex: Their
prevalence, natural course, and diagnostic significance</article-title>
<source/>Int J Dermatol
          <volume>37</volume>
<fpage>911</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="pmid">9888331</pub-id>
</element-citation>
</ref>
<ref id="B24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knudson</surname>
<given-names>AG</given-names>
</name>
</person-group>
<year>1971</year>
<article-title>Mutation and cancer: Statistical study of
retinoblastoma</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>68</volume>
<fpage>820</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="pmid">5279523</pub-id>
</element-citation>
</ref>
<ref id="B25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kothare</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chalifoux</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Menzer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Severity of manifestations in tuberous sclerosis complex in relation
to genotype</article-title>
<source/>Epilepsia
          <volume>55</volume>
<fpage>1025</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="pmid">24917535</pub-id>
</element-citation>
</ref>
<ref id="B26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumasaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Seyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mitani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Souma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Minami</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uekusa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fukuchi</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<year>2004</year>
<article-title>Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the
progression of lymphangioleiomyomatosis</article-title>
<source/>Am J Surg Pathol
          <volume>28</volume>
<fpage>1007</fpage>
<lpage>1016</lpage>
<pub-id pub-id-type="pmid">15252306</pub-id>
</element-citation>
</ref>
<ref id="B27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwiatkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Henske</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Braiser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wigowska-Sowinska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kasprzyk-Obara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<year>1998</year>
<article-title>Comprehensive mutational analysis of the TSC1 gene: Observations on
frequency of mutation, associated features, and nonpenetrance</article-title>
<source/>Ann Hum Genet
          <volume>62</volume>
<fpage>277</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="pmid">9924605</pub-id>
</element-citation>
</ref>
<ref id="B28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<year>2003</year>
<article-title>Rhebbing up mTor: New insights on TSC1 and TSC2, and the pathogenesis
of tuberous sclerosis</article-title>
<source/>Cancer Biol Ther
          <volume>2</volume>
<fpage>471</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="pmid">14614311</pub-id>
</element-citation>
</ref>
<ref id="B29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langkau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zügge</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Quast</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wiegele</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jauch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rehm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuhl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mack-Vetter</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2002</year>
<article-title>
<italic>TSC1</italic> and <italic>TSC2</italic> mutations in tuberous sclerosis,
the associated phenotypes and a model to explain observed TSC1/TSC2 frequency
ratios</article-title>
<source/>Eur J Pediatr
          <volume>161</volume>
<fpage>393</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">12111193</pub-id>
</element-citation>
</ref>
<ref id="B30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maheshwar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cheadle</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Myring</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>The GAP-related domain of tuberin, the product of the TSC2 gene, is a
target for missense mutations in tuberous sclerosis</article-title>
<source/>Hum Mol Genet
          <volume>6</volume>
<fpage>1991</fpage>
<lpage>1996</lpage>
<pub-id pub-id-type="pmid">9302281</pub-id>
</element-citation>
</ref>
<ref id="B31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>GX</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Mutation screening of <italic>TSC1</italic> and <italic>TSC2</italic>
genes in Chinese Han children with tuberous sclerosis complex</article-title>
<source/>Genet Mol Res
          <volume>13</volume>
<fpage>2102</fpage>
<lpage>2106</lpage>
<pub-id pub-id-type="pmid">24737435</pub-id>
</element-citation>
</ref>
<ref id="B32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzykewicz</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muse</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Numis</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>
<italic>TSC1</italic> and <italic>TSC2</italic> mutations in patients with
lymphangioleiomyomatosis and tuberous sclerosis complex</article-title>
<source/>J Med Genet
          <volume>46</volume>
<fpage>465</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">19419980</pub-id>
</element-citation>
</ref>
<ref id="B33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lawrence-Smith</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Banwell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beauchamp</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ozelius</surname>
<given-names>L</given-names>
</name>
</person-group>
<year>1999</year>
<article-title>Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated
patients with tuberous sclerosis</article-title>
<source/>Hum Mutat
          <volume>14</volume>
<fpage>412</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="pmid">10533067</pub-id>
</element-citation>
</ref>
<ref id="B34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>RA</given-names>
</name>
</person-group>
<year>1993</year>
<article-title>Variability of expression in tuberous sclerosis</article-title>
<source/>J Med Genet
          <volume>30</volume>
<fpage>41</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">8423606</pub-id>
</element-citation>
</ref>
<ref id="B35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<collab>International Tuberous Sclerosis Complex Consensus Group</collab>
</person-group>
<year>2013</year>
<article-title>Tuberous sclerosis complex diagnostic criteria update: Recommendations
of the 2012 International Tuberous Sclerosis Complex Consensus
Conference</article-title>
<source/>Pediatr Neurol
          <volume>49</volume>
<fpage>243</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">24053982</pub-id>
</element-citation>
</ref>
<ref id="B36">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>O’Callaghan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>J</given-names>
</name>
</person-group>
<year>2010</year>
<chapter-title>Endocrine, gastrointestinal, hepatic, and lymphatic
manifestations of tuberous sclerosis complex</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Kwiatkowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Whittemore</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>E</given-names>
</name>
</person-group>
<source/>Tuberous Sclerosis Complex: Genes, Clinical Features, and
Therapeutics
          <publisher-name>Wiley-Blackwell</publisher-name>
<publisher-loc>Weinheim</publisher-loc>
<fpage>369</fpage>
<lpage>385</lpage>
</element-citation>
</ref>
<ref id="B37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>D</given-names>
</name>
</person-group>
<year>1991</year>
<article-title>Epidemiology of tuberous sclerosis</article-title>
<source/>Ann NY Acad Sci
          <volume>615</volume>
<fpage>25</fpage>
<lpage>127</lpage>
</element-citation>
</ref>
<ref id="B38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Mathern</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Taillon</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Bouffard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Analysis of TSC cortical tubers by deep sequencing of <italic>TSC1,
TSC2</italic> and <italic>KRAS</italic> demonstrates that small second-hit
mutations in these genes are rare events</article-title>
<source/>Brain Pathol
          <volume>20</volume>
<fpage>1096</fpage>
<lpage>1105</lpage>
<pub-id pub-id-type="pmid">20633017</pub-id>
</element-citation>
</ref>
<ref id="B39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rendtorff</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Bjerregaard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Frodin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kjaergaard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hove</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Skovby</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brøndum-Nielsen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M</given-names>
</name>
<collab>Danish Tuberous Sclerosis Group</collab>
</person-group>
<year>2005</year>
<article-title>Analysis of 65 Tuberous Sclerosis complex (TSC) patients by
<italic>TSC2</italic> DGGE<italic>, TSC1/TSC2</italic> MLPA, and
<italic>TSC1</italic> Long-Range PCR Sequencing, and report of 28 novel
mutations</article-title>
<source/>Hum Mutat
          <volume>26</volume>
<fpage>374</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="pmid">16114042</pub-id>
</element-citation>
</ref>
<ref id="B40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roach</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
</person-group>
<year>1998</year>
<article-title>Tuberous sclerosis complex consensus conference: Revised clinical
diagnostic criteria</article-title>
<source/>J Child Neurol
          <volume>13</volume>
<fpage>624</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">9881533</pub-id>
</element-citation>
</ref>
<ref id="B41">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>DM</given-names>
</name>
</person-group>
<year>1999</year>
<chapter-title>Ophthalmic findings</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Whittemore</surname>
<given-names>VH</given-names>
</name>
</person-group>
<source/>Tuberous Sclerosis Complex
          <edition>3rd ed.</edition>
<publisher-name>Oxford University Press</publisher-name>
<publisher-loc>New York</publisher-loc>
<fpage>145</fpage>
<lpage>159</lpage>
</element-citation>
</ref>
<ref id="B42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rok</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kasprzyk-Obara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Domanska-Pakiela</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Józwiak</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Clinical symptoms of tuberous sclerosis complex in patients with an
identical <italic>TSC2</italic> mutation</article-title>
<source/>Med Sci Monit
          <volume>11</volume>
<fpage>230</fpage>
<lpage>234</lpage>
</element-citation>
</ref>
<ref id="B43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowley</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>O’Callaghan</surname>
<given-names>FJO</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<year>2001</year>
<article-title>Ophthalmic manifestations of tuberous sclerosis: A population based
study</article-title>
<source/>Br J Ophthalmol
          <volume>85</volume>
<fpage>420</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="pmid">11264130</pub-id>
</element-citation>
</ref>
<ref id="B44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Maheshwar</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Aspinwall</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cheadle</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Ravine</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>PC</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>Renal cystic disease in tuberous sclerosis: Role of the polycystic
kidney disease 1 gene</article-title>
<source/>Am J Hum Genet
          <volume>61</volume>
<fpage>843</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="pmid">9382094</pub-id>
</element-citation>
</ref>
<ref id="B45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancak</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goedbloed</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elfferich</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maat-Kievit</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Verhoef</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van den Ouweland</surname>
<given-names>A</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Mutational analysis of the TSC1 and TSC2 genes in a diagnostic
setting: Genotype-phenotype correlations and comparison of diagnostic DNA
techniques in Tuberous Sclerosis Complex</article-title>
<source/>Eur J Hum Genet
          <volume>13</volume>
<fpage>731</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="pmid">15798777</pub-id>
</element-citation>
</ref>
<ref id="B46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasongko</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Wataya-Kaneda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koterazawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gunadi</surname>
<given-names>Yusoff S</given-names>
</name>
<name>
<surname>Harahap</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>H</given-names>
</name>
</person-group>
<year>2008</year>
<article-title>Novel mutations in 21 patients with tuberous sclerosis complex and
variation of tandem splice-acceptor sites in <italic>TSC1</italic> exon
14</article-title>
<source/>Kobe J Med Sci
          <volume>54</volume>
<fpage>73</fpage>
<lpage>81</lpage>
</element-citation>
</ref>
<ref id="B47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kotulska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2007</year>
<article-title>Tuberous sclerosis complex: Advances in diagnosis, genetics, and
management</article-title>
<source/>J Am Acad Dermatol
          <volume>57</volume>
<fpage>189</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">17637444</pub-id>
</element-citation>
</ref>
<ref id="B48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serfontein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nisbet</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Conservation of structural and functional elements of TSC1 and TSC2: A
bioinformatic comparison across animal models</article-title>
<source/>Behav Genet
          <volume>41</volume>
<fpage>349</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="pmid">21243421</pub-id>
</element-citation>
</ref>
<ref id="B49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lie</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Crowson</surname>
<given-names>CS</given-names>
</name>
</person-group>
<year>1991</year>
<article-title>Causes of death in patients with tuberous sclerosis</article-title>
<source/>Mayo Clin Proc
          <volume>66</volume>
<fpage>792</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="pmid">1861550</pub-id>
</element-citation>
</ref>
<ref id="B50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>XF</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>KH</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Cutaneous lesions and visceral involvement of tuberous
sclerosis</article-title>
<source/>Chin Med J (Engl)
          <volume>118</volume>
<fpage>215</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">15740650</pub-id>
</element-citation>
</ref>
<ref id="B51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Three novel mutations of <italic>TSC1</italic> gene in Chinese
patients with tuberous sclerosis complex</article-title>
<source/>Int J Dermatol
          <volume>52</volume>
<fpage>1274</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="pmid">24073908</pub-id>
</element-citation>
</ref>
<ref id="B52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Eeghena</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Eeghena</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Central <italic>TSC2</italic> missense mutations are associated with a
reduced risk of infantile spasms</article-title>
<source/>Epilepsy Res
          <volume>103</volume>
<fpage>83</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">22867869</pub-id>
</element-citation>
</ref>
<ref id="B53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<year>1996</year>
<article-title>Morbidity associated with tuberous sclerosis: A population
study</article-title>
<source/>Dev Med Child Neurol
          <volume>38</volume>
<fpage>146</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="pmid">8603782</pub-id>
</element-citation>
</ref>
<ref id="B54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamotoa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pipob</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Fengb</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nanba</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ninomiya</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
</person-group>
<year>2002</year>
<article-title>Novel <italic>TSC1</italic> and <italic>TSC2</italic> mutations in
Japanese patients with tuberous sclerosis complex</article-title>
<source/>Brain Dev
          <volume>24</volume>
<fpage>227</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">12015165</pub-id>
</element-citation>
</ref>
<ref id="B55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yates</surname>
<given-names>JR</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Tuberous sclerosis</article-title>
<source/>Eur J Hum Genet
          <volume>14</volume>
<fpage>1065</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="pmid">16868562</pub-id>
</element-citation>
</ref>
<ref id="B56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Two novel <italic>TSC2</italic> mutations in Chinese patients with
tuberous sclerosis complex</article-title>
<source/>Indian J Dermatol Venereol Leprol
          <volume>79</volume>
<fpage>104</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="pmid">23254740</pub-id>
</element-citation>
</ref>
</ref-list>
<ref-list>
<title>Internet resources</title>
<ref id="B57">
<element-citation publication-type="webpage">
<source/>HGMD - Human Genome Mutation Database
          <comment>
<ext-link ext-link-type="uri" xlink:href="http://www.hgmd.cf.ac.uk/ac/index.php">http://www.hgmd.cf.ac.uk/ac/index.php</ext-link>
</comment>
<date-in-citation content-type="access-date">accessed in November,
2014</date-in-citation>
</element-citation>
</ref>
<ref id="B58">
<element-citation publication-type="webpage">
<source/>LOVD - Leiden Open Variation Database
          <comment>(<ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/3.0/home">http://www.lovd.nl/3.0/home</ext-link>)</comment>
<date-in-citation content-type="access-date">access in November,
2014</date-in-citation>
</element-citation>
</ref>
<ref id="B59">
<element-citation publication-type="webpage">
<source/>Orphanet: Tuberous Sclerosis
          <comment>
<ext-link ext-link-type="uri" xlink:href="http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&amp;data_id=660&amp;MISSING%20CONTENT=Tuberous-sclerosis&amp;search=Disease_Search_Simple&amp;title=Tuberous-sclerosis">http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&amp;data_id=660&amp;MISSING%20CONTENT=Tuberous-sclerosis&amp;search=Disease_Search_Simple&amp;title=Tuberous-sclerosis</ext-link>
</comment>
<date-in-citation content-type="access-date">(accessed in May,
2015)</date-in-citation>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>